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Over the last two decades, an increasing number of disease modifying therapies have 
emerged that reduce relapses and relapse-related disability in patients with the relapsing-
remitting form of multiple sclerosis (RRMS). Around a dozen therapies are now licensed for 
the treatment of RRMS in North America and Europe, with efficacy in terms of relapse rate 
reduction ranging from 30-75%.  
In contrast to RRMS, there has been very limited progress in the development of therapies 
to favourably modify the course of progressive MS, whether it occurs from clinical onset 
(primary progressive MS [PPMS]) or after a relapsing remitting phase (secondary progressive 
MS [SPMS]). Indeed, it was only earlier this year that the first disease modifying therapy for 
PPMS gained regulatory approval in the United States, albeit with only a partial effect in 
slowing disease progression.1,2 The progressive phase of MS typically leads to irreversible 
neurological disability often with cognitive impairment, which emphasises the pressing need 
to develop new and more effective treatments to substantially slow or even halt this phase 
of MS.  
A key reason for the timely development of multiple effective therapies for RRMS was use 
of the new and/or active inflammatory lesion, as seen on serial magnetic resonance imaging 
(MRI) scans, as a primary outcome measure in relatively small and short term phase 2 
clinical trials. At the study arm level, a demonstrable treatment-associated reduction in 
new/active MRI lesions in phase 2 trials has been followed by a treatment-associated 
reduction in relapse rate in subsequent larger and longer phase 3 trials3. Thus the pipeline 
from successful phase 2 to 3 trials has been expedited in RRMS.  
There are multiple challenges to the development of effective disease modifying therapies 
for progressive MS4. These include a limited understanding of its pathogenesis, challenges in 
its clinical definition, and the high cost and logistical burden of undertaking the phase 3 
trials that are required to show a reduction in the accumulation of disability. Unlike RRMS, 
there is, as yet, no widely accepted or robustly evidence-based surrogate measure that, 
when used in a short term phase 2 trial, can identify agents that will likely be shown to be 
clinically beneficial (in this setting that they will prevent disability progression) in phase 3. 
Not surprisingly, there have been many negative phase 3 trials in progressive MS. 
The 2017 ECTRIMS focused workshop was held in Rome on March 9th and 10th, in 
association with the International Progressive MS Alliance. It was developed to create a 
forum for detailed consideration of strategies to improve the design of trials in progressive 
MS, with the ultimate aim to expedite the trial pipeline and introduce effective treatments 
more quickly.  
The invited workshop participants covered a wide range of expertise, including neurology, 
neuropathology, neuroradiology, trial design, statistical, pharmaceutical, regulatory and lay 
viewpoints. Themes included treatment targets, trials thus far, clinical outcome measures, 
and interim outcome measures. The latter tended to focus on neuroprotection because 
there is robust evidence that neurodegeneration (albeit due to multiple mechanisms4,5) is a 
key pathological substrate of progressive MS.  In addition to MRI, for which some 
preliminary evidence for a treatment-responsive neuroprotective outcome measure exists6, 
potential interim outcomes measures included those derived from optical coherence 
tomography, positron emission tomography, serum and cerebrospinal fluid (especially 
neurofilaments), and neurophysiology. There were also sessions that considered types of 
trial design, statistical analysis methodology, observations from big datasets, phase 2 trials 
in progress, and considerations from a pharmaceutical and regulatory perspective. 
It was felt that the best way of communicating the workshop proceedings more widely 
would be through a Themed Issue of the Multiple Sclerosis Journal. In this issue, a series of 
papers have been assembled under the Guest Editorship of Jeremy Chataway and Robert 
Fox. Development of the content was assisted from notes made during the workshop by 
Carmen Tur and Daniel Ontaneda. Authors of the papers were also workshop participants. 
The papers collectively provide an account of current and emerging knowledge relevant to 
the design of trials in progressive MS. We hope that the information collated in this Themed 
Issue will be helpful in the ongoing effort to expedite effective treatments for this most 
disabling phase of MS.  
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